Project Grant K99DK137029
Award Date
8/6/24
Completion Date
5/31/26
Dollars Obligated
$272K
Similar Awards
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $243,590 to the University of Chicago to investigate the role of the protein BNIP3 in regulating lipid homeostasis in the liver. The goal is to define the mechanisms by which BNIP3 influences the accumulation of lipid droplets, which is a key factor in the development of non-alcoholic...
The federal Project Grant award R01DK140159, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to investigate the potential of a novel adipokine in resolving non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in animal models. The $469,235 award, with a start date of September 1, 2024, and an ultimate completion date of June 30,...
This $806,452 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research investigating the mechanisms that combine type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). The research aims to determine how hepatic insulin resistance can lead to the progression of NAFLD to the more severe non-alcoholic steatohepatitis (NASH), and how this...
This $754,400 Project Grant award was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research (CFDA 93.847) program. The funding will support research by The University of Texas Southwestern Medical Center (UT Southwestern) to identify adaptive genetic pathways and understand how mutant clones expand within chronically damaged liver tissues, with the goal of developing therapeutic approaches...
The U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a Project Grant (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) to the Icahn School of Medicine at Mount Sinai totaling $707,389.00 on August 15, 2024. The grant supports a 5-year study titled "Targeting Nonalcoholic Fatty Liver Disease During the Reproductive Period to Improve Women's Health Outcomes". The study aims to: 1) Determine the association between...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research program) provides $172,300.00 to the University of California, Los Angeles (UCLA) to investigate the role of peroxisomal PEX family proteins in regulating hepatic bile acid and lipid metabolism. The research aims to describe how the loss of PEX6 and PEX14 proteins impacts lipid homeostasis and inter-organelle crosstalk...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $1,428,186 Project Grant under CFDA 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research) to Beth Israel Deaconess Medical Center, Inc. (Bidmc) in Boston, MA. The grant, effective January 1, 2025 through December 31, 2029, will fund research to biochemically characterize N-acyl amino acids as substrates and competitive inhibitors of CYP4F enzymes, define the functional consequences of N-acyl...
This federal Project Grant award, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to investigate the role of the carbohydrate responsive element binding protein (ChREBP) and its isoforms in liver metabolism, metabolic diseases, and associated steatohepatitis. The $626,429 award, effective from July 1, 2025 to May 31, 2030, will employ genetic interventions...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) supports research to understand the underlying mechanisms of non-alcoholic steatohepatitis (NASH), a liver disease that is expected to become the leading indication for liver transplantation. The $172,060 award to The General Hospital Corporation (doing business as Massachusetts General Hospital) aims to investigate how...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to define the role of antigen-specific T cell responses in the progression of non-alcoholic steatohepatitis (NASH), a chronic liver disease. The $599,541 award, with a project period from September 2024 to August 2025, will fund research at the University of Colorado-Denver to investigate:...